Life Sciences Player Repligen’s Strategic European Acquisition – What It Means for Investors
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported
Novo Nordisk’s Obesity Drug Saxenda Not Included In WHO’s Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,
Roche’s Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)
Analyst Says Nektar Therapeutics’ Rezpeg Prioritization Likely to Spark Investor Questions
Nektar Therapeutics (NASDAQ:NKTR) announced a strategic plan to reprioritize assets and restructure costs. Regarding clinical programs, Nektar will prioritize the…
FDA Issues Partial Clinical Hold On Merck Germany’s Multiple Sclerosis Study
The FDA has placed a partial clinical hold on initiating new patients on Germany’s Merck KGaA’s (OTC:MKGAF) (OTC:MKKGY) evobrutinib and patients with…
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Germany’s Merck KGaA (OTC: MKGAF) (OTC: MKKGY) has regained exclusive worldwide rights to develop, manufacture, and commercialize its checkpoint blocker Bavencio (avelumab) from Pfizer Inc (NYSE:PFE).…
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
The FDA granted accelerated approval to Incyte Corporation’s (NASDAQ:INCY) Zynyz (retifanlimab-dlwr) for adult patients with metastatic or recurrent locally advanced Merkel cell…